Organigram Holdings stock (CA68620P1018): Q2 2026 results show revenue drop, raised FY guidance

Organigram Holdings Inc., trading as OGI on Nasdaq and the Toronto Stock Exchange, announced its second quarter fiscal 2026 results for the period ended March 31, 2026, on May 13, 2026. Net revenue fell 9% to C$59.8 million from C$65.6 million in the prior year, driven by a decline in recreational cannabis sales, according to StockTitan as of 05/13/2026. Despite the dip, Organigram maintained its position as Canada's top licensed producer by market share and raised its full-year revenue guidance.

The company also highlighted its ongoing European expansion through the Sanity Group deal, which extends its reach in the cannabis market, as noted in TipRanks as of 05/13/2026. Organigram forecasted strong adjusted EBITDA for FY26 alongside low capital expenditures, signaling confidence in cost controls and growth prospects.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Organigram Holdings: core business model

Organigram Holdings operates as a leading licensed producer of cannabis and cannabis-derived products in Canada, focusing on high-quality flower, oils, and consumer packaged goods for wholesale and retail channels. Headquartered in Moncton, New Brunswick, the company cultivates in state-of-the-art facilities exceeding one million square feet, as detailed in its Q2 fiscal 2026 earnings materials published May 13, 2026.

The business model emphasizes premium brands like Edison Cannabis Co. and SHIMAYA, targeting recreational and medical markets. Organigram supplies major provincial boards, including Ontario and British Columbia, where it holds leading market shares, according to Investing.com as of 05/13/2026.

Main revenue and product drivers for Organigram Holdings

Recreational cannabis remains the primary revenue driver, though Q2 fiscal 2026 saw a decline due to market pressures. Net revenue totaled C$59.8 million for the quarter ended March 31, 2026, down 9% from the year-ago period, per the company's SEC filing on May 13, 2026. International expansion via the Sanity Group partnership is poised to diversify revenue streams into Europe.

Key products include dried flower, vapes, and edibles, with a focus on innovation in extracts and international formats. The company reported maintaining #1 market share in Canada during Q2 fiscal 2026, as stated in its earnings release on Investing News Network as of 05/13/2026.

Industry trends and competitive position

The Canadian cannabis sector faces pricing pressures and consolidation, yet Organigram's leadership in market share—particularly in Ontario—provides a competitive edge. U.S. investors may note the company's Nasdaq listing (OGI), offering exposure to global cannabis trends amid potential U.S. regulatory shifts.

Why Organigram Holdings matters for US investors

Listed on Nasdaq as OGI, Organigram provides U.S. retail investors direct access to Canada's mature cannabis market, the world's first fully legal recreational framework. Its European push via Sanity Group adds diversification, relevant as U.S. multi-state operators eye federal reforms.

Conclusion

Organigram Holdings' Q2 fiscal 2026 results reflect challenges in Canadian recreational sales but underscore resilience with raised FY26 guidance and European momentum. The company's market leadership and cost discipline position it amid sector headwinds. U.S. investors tracking cannabis via Nasdaq OGI will monitor execution on international growth and domestic stabilization.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.